REPH yields 95.69% · MRK yields 3.25%● Live data
📍 REPH pulled ahead of the other in Year 1
Combined, REPH + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of REPH + MRK for your $10,000?
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Full REPH Calculator →Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.